- Home
- MGIC vs SLRX Comparison
MGIC vs SLRX Comparison
Compare MGIC & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- SLRX
- Stock Information
- Founded
- MGIC 1983
- SLRX N/A
- Country
- MGIC Israel
- SLRX United States
- Employees
- MGIC N/A
- SLRX N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- SLRX Health Care
- Exchange
- MGIC Nasdaq
- SLRX Nasdaq
- Market Cap
- MGIC 990.3M
- SLRX 2.9M
- IPO Year
- MGIC 1991
- SLRX N/A
- Fundamental
- Price
- MGIC $19.39
- SLRX $5.56
- Analyst Decision
- MGIC Buy
- SLRX
- Analyst Count
- MGIC 2
- SLRX 0
- Target Price
- MGIC $18.00
- SLRX N/A
- AVG Volume (30 Days)
- MGIC 41.9K
- SLRX 286.4K
- Earning Date
- MGIC 11-17-2025
- SLRX 11-13-2025
- Dividend Yield
- MGIC 2.91%
- SLRX N/A
- EPS Growth
- MGIC 16.93
- SLRX N/A
- EPS
- MGIC 0.78
- SLRX N/A
- Revenue
- MGIC $584,528,000.00
- SLRX N/A
- Revenue This Year
- MGIC $11.11
- SLRX N/A
- Revenue Next Year
- MGIC $6.83
- SLRX N/A
- P/E Ratio
- MGIC $25.76
- SLRX N/A
- Revenue Growth
- MGIC 11.98
- SLRX N/A
- 52 Week Low
- MGIC $10.42
- SLRX $4.50
- 52 Week High
- MGIC $22.00
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- MGIC 42.26
- SLRX 43.47
- Support Level
- MGIC $19.79
- SLRX $4.79
- Resistance Level
- MGIC $20.80
- SLRX $5.90
- Average True Range (ATR)
- MGIC 0.50
- SLRX 0.40
- MACD
- MGIC -0.03
- SLRX 0.27
- Stochastic Oscillator
- MGIC 31.46
- SLRX 75.36
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.